Effects of active MEK1 expression in vivo
- PMID: 16253755
- DOI: 10.1016/j.canlet.2004.12.013
Effects of active MEK1 expression in vivo
Abstract
Cell transformation is often a result of constitutive activation of genes in signaling pathways that regulate cell proliferation and differentiation. Indeed, the Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway is constitutively activated in a large number of cancers. The extent to which a single-gene mutation can alter cell fate, however, remains questionable. In vitro studies have addressed this issue, but organs are comprised of multiple cell types, and in vitro models often poorly approximate these interactions. In response to these limitations, cell-type specific mouse models have been generated as a means to examine the effect of altering a single element of the MAPK pathway in vivo. This review summarizes data from transgenic murine and human tissue models expressing constitutive active forms of MEK1.
Similar articles
-
Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.Clin Cancer Res. 2008 Oct 15;14(20):6396-404. doi: 10.1158/1078-0432.CCR-07-5113. Clin Cancer Res. 2008. PMID: 18927278
-
Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia.Dev Cell. 2007 Apr;12(4):615-29. doi: 10.1016/j.devcel.2007.03.009. Dev Cell. 2007. PMID: 17419998
-
Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.Oncogene. 2007 Feb 8;26(6):813-21. doi: 10.1038/sj.onc.1209843. Epub 2006 Aug 7. Oncogene. 2007. PMID: 16909118
-
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.Oncogene. 2007 May 14;26(22):3291-310. doi: 10.1038/sj.onc.1210422. Oncogene. 2007. PMID: 17496923 Review.
-
The RASputin effect.Genes Dev. 2002 Aug 15;16(16):2033-8. doi: 10.1101/gad.1020602. Genes Dev. 2002. PMID: 12183358 Review. No abstract available.
Cited by
-
Ectopic ERK expression induces phenotypic conversion of C10 cells and alters DNA methyltransferase expression.BMC Res Notes. 2012 May 4;5:217. doi: 10.1186/1756-0500-5-217. BMC Res Notes. 2012. PMID: 22559742 Free PMC article.
-
BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer.EBioMedicine. 2017 Jun;20:50-60. doi: 10.1016/j.ebiom.2017.05.001. Epub 2017 May 4. EBioMedicine. 2017. PMID: 28501528 Free PMC article.
-
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.J Clin Oncol. 2020 Nov 10;38(32):3753-3762. doi: 10.1200/JCO.20.01164. Epub 2020 Aug 21. J Clin Oncol. 2020. PMID: 32822286 Free PMC article. Clinical Trial.
-
The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.Blood. 2011 Jul 28;118(4):1052-61. doi: 10.1182/blood-2011-03-340109. Epub 2011 May 31. Blood. 2011. PMID: 21628402 Free PMC article.
-
Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.Clin Cancer Res. 2018 Nov 15;24(22):5525-5533. doi: 10.1158/1078-0432.CCR-18-0494. Epub 2018 May 29. Clin Cancer Res. 2018. PMID: 29844129 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous